Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

This phase 2, open-label, multicenter study evaluated the efficacy and safety of brentuximab vedotin, a CD30-directed antibody-drug conjugate, in relapsed/refractory CD30(+) non-Hodgkin lymphomas. The primary end point was objective response rate (ORR). Key secondary end points included safety, corr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Horwitz, Steven M., Advani, Ranjana H., Bartlett, Nancy L., Jacobsen, Eric D., Sharman, Jeff P., O’Connor, Owen A., Siddiqi, Tanya, Kennedy, Dana A., Oki, Yasuhiro
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425442/
https://ncbi.nlm.nih.gov/pubmed/24652992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-542142
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados